Differential Effects of Sertraline and Penfluridol on EMT and ECM Remodeling in Glioblastoma Cell Lines

Abstract

Background and Purpose: Glioblastoma multiforme (GBM) is an aggressive brain tumor with poor prognosis due to rapid recurrence, chemoresistance, and limited efficacy of standard therapies. Epithelial-to-mesenchymal transition (EMT) and matrix metalloproteinase (MMP)-mediated extracellular matrix (ECM) remodeling are critical processes in GBM progression and metastasis. The aim of this study is to examine the potential effects of sertraline and penfluridol on the EMT process and gelatinase activity in human glioblastoma cell lines. Methods: U87 and U251 human glioblastoma cells were treated with sertraline and penfluridol at previously identified IC50 doses. Protein levels of EMT markers, E-cadherin, vimentin, Snail, Slug, Twist1, phospho-Akt (p-Akt), and tissue inhibitor of metalloproteinases-2 (TIMP-2), were evaluated using Western blotting. Additionally, the impact of sertraline and penfluridol on the release and activity of MMP-2 and MMP-9 were assessed through gelatin zymography. Results: Both sertraline and penfluridol significantly reduced vimentin expression in U251 cells, indicating inhibition of the mesenchymal phenotype. Conversely, these drugs increased vimentin levels in U87 cells, highlighting cell line-specific differences. Sertraline and penfluridol also increased TIMP-2 levels in U251 cells but not in U87 cells. Neither drug altered MMP-2 or MMP-9 activity in either cell line, suggesting that their effects on ECM remodeling may be mediated through TIMP-2 upregulation rather than direct modulation of gelatinase activity. Conclusion: These findings suggest that sertraline and penfluridol potentially inhibit EMT and reduce ECM degradation in U251 cells but exert contrasting effects in U87 cells. This highlights the heterogeneity of GBM tumors and the importance of personalized therapeutic approaches.

Keywords

• Sertralin
• Penfluridol
• Glioblastoma
• Epithelial-mesenchymal transition
• Matrix metalloproteinases

Supporting Institution

İzmir University of Economics

Project Number

none

Ethical Statement

Ethical approval was obtained from the Health Sciences Research Ethics Committee of Izmir University of Economics, Izmir, Turkey (Ethics Committee No: B.30.2.İEÜSB.0.05.05-20-320; date: 17/09/2024).

Thanks

We extend our gratitude to Erdoğan Pekcan Erkan for providing the U251 and U87 glioblastoma cell lines.

References

1. Wu W, Klockow JL, Zhang M, et al. Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. Pharmacol Res 2021;171:105780.
2. Javaid JI. Clinical pharmacokinetics of antipsychotics. J Clin Pharmacol 1994;34(4):286-95.
3. Sheehan DV, Kamijima K. An evidence-based review of the clinical use of sertraline in mood and anxiety disorders. Int Clin Psychopharmacol 2009;24(2):43-60.
4. Torta R, Siri I, Caldera P. Sertraline effectiveness and safety in depressed oncological patients. Support Care Cancer 2008;16(1):83-91.
5. Janssen PA, Niemegeers CJ, Schellekens KH, Lenaerts FM, Verbruggen FJ, Van Nueten JM, Schaper WK. The pharmacology of penfluridol (R 16341) a new potent and orally long-acting neuroleptic drug. Eur J Pharmacol 1970;11(2):139-154.
6. Soares BG, Lima MS. Penfluridol for schizophrenia. Cochrane Database Syst Rev 2006;(2):CD002923.
7. Ranjan A, Srivastava SK. Penfluridol suppresses glioblastoma tumor growth by Akt-mediated inhibition of GLI1. Oncotarget 2017;8(20):32960-32976.
8. Gil-Ad I, Zolokov A, Lomnitski L, et al. Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice. Int J Oncol 2008;33(2):277-286.

9. Kuwahara J, Yamada T, Egashira N, Ueda M, Zukeyama N, Ushio S, Masuda S. Comparison of the Anti-tumor Effects of Selective Serotonin Reuptake Inhibitors as Well as Serotonin and Norepinephrine Reuptake Inhibitors in Human Hepatocellular Carcinoma Cells. Biol Pharm Bull 2015;38(9):1410-1414.
10. Ranjan A, Gupta P, Srivastava SK. Penfluridol: An Antipsychotic Agent Suppresses Metastatic Tumor Growth in Triple-Negative Breast Cancer by Inhibiting Integrin Signaling Axis. Cancer Res 2016;76(4):877-890.
11. Gwynne WD, Hallett RM, Girgis-Gabardo A, et al. Serotonergic System Antagonists Target Breast Tumor Initiating Cells and Synergize with Chemotherapy to Shrink Human Breast Tumor Xenografts. Oncotarget 2017;8:32101–32116.
12. Dandawate P, Kaushik G, Ghosh C, et al. Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice. Gastroenterology 2020;158(5):1433-1449.
13. Ranjan A, Srivastava SK. Penfluridol suppresses pancreatic tumor growth by autophagy-mediated apoptosis. Sci Rep 2016; 6, 26165.
14. Tuynder M, Fiucci G, Prieur S, et al. Translationally controlled tumorprotein is a target of tumor reversion. Proc Natl Acad Sci 2004;101(43):15364-15369.
15. Brabletz T, Kalluri R, Nieto MA, Weinberg RA. EMT in cancer. Nat Rev Cancer 2018;18(2):128-134.
16. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009;28(1-2):15-33.
17. Mustafa S, Koran S, AlOmair L. Insights Into the Role of Matrix Metalloproteinases in Cancer and its Various Therapeutic Aspects: A Review. Front Mol Biosci 2022;9:896099.
18. Iser IC, Pereira MB, Lenz G, Wink MR. The Epithelial-to-Mesenchymal Transition-Like Process in Glioblastoma: An Updated Systematic Review and In Silico Investigation. Med Res Rev 2017;37(2):271-313.
19. Bartık Keles D. Evaluation of the Effects of Sertraline and Penfluridol on Tumorigenesis and Metastatic Cell Behavior in Human Glioblastoma Cells: Drug Repositionings. Dokuz Eylül University. 2019
20. Banyard J, Bielenberg DR. The role of EMT and MET in cancer dissemination. Connect Tissue Res 2015;56(5):403-413.
21. Lewis-Tuffin LJ, Rodriguez F, Giannini C, Scheithauer B, Necela BM, Sarkaria JN, Anastasiadis PZ. Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype. PLoS One 2010;5(10):e13665.
22. Li J, Qu J, Shi Y, et al. Nicotinic acid inhibits glioma invasion by facilitating Snail1 degradation. Sci Rep 2017;7:43173.
23. Motaln H, Koren A, Gruden K, Ramšak Ž, Schichor C, Lah TT. Heterogeneous glioblastoma cell cross-talk promotes phenotype alterations and enhanced drug resistance. Oncotarget 2015;6(38):40998-41017.
24. Gupta N, Gupta P, Srivastava SK. Penfluridol overcomes paclitaxel resistance in metastatic breast cancer. Sci Rep 2019;9(1):5066.
25. Xue Q, Liu Z, Feng Z, et al. Penfluridol: An antipsychotic agent suppresses lung cancer cell growth and metastasis by inducing G0/G1 arrest and apoptosis. Biomed Pharmacother 2020;121:109598.
26. Hung WY, Lee WJ, Cheng GZ, et al. Blocking MMP-12-modulated epithelial-mesenchymal transition by repurposing penfluridol restrains lung adenocarcinoma metastasis via uPA/uPAR/TGF-β/Akt pathway. Cell Oncol (Dordr) 2021;44(5):1087-1103.
27. Kim H, Chong K, Ryu BK, et al. Repurposing Penfluridol in Combination with Temozolomide for the Treatment of Glioblastoma. Cancers (Basel) 2019;11(9):1310.
28. Baldissera AB, Boia-Ferreira M, Basílio ABC, et al. Sertraline as a potential cancer therapeutic approach: Biological relevance of TCTP in breast cancer cell lines and tumors. Adv Med Sci 2023;68(2):227-237.
29. Chinnapaka S, Bakthavachalam V, Munirathinam G. Repurposing antidepressant sertraline as a pharmacological drug to target prostate cancer stem cells: dual activation of apoptosis and autophagy signaling by deregulating redox balance. Am J Cancer Res 2020;10(7):2043-2065.
30. Duarte D, Rêma A, Amorim I, Vale N. Drug Combinations: A New Strategy to Extend Drug Repurposing and Epithelial-Mesenchymal Transition in Breast and Colon Cancer Cells. Biomolecules 2022;12(2):190.